The US Food and Drug Administration has approved the first oral pill for treating anaemia in adults with thalassemia, a significant development according to health experts. Mitapivat, to be sold as Aqvesme, is now authorized for managing anemia in adults with alpha- or beta-thalassemia. This medication is the first of its kind for both transfusion-dependent and non-transfusion-dependent forms of these rare genetic blood disorders.
Mitapivat’s approval is expected to revolutionize thalassemia management, shifting the reliance from traditional treatments like transfusions and chelation therapy. Dr. Satyam Arora from PGICH, Noida, believes that this new drug could be groundbreaking, simplifying patient care with a single oral pill and potentially reducing the need for blood transfusions. Experts suggest that besides boosting haemoglobin levels, this oral option might alleviate fatigue, lessen treatment burdens, and decrease long-term complications for patients.
Mitapivat, a pyruvate kinase activator, works by enhancing energy balance within red blood cells, a crucial mechanism in thalassemia patients. By improving cellular energy production, this drug helps red blood cells survive longer and function better, ultimately reducing the necessity for frequent blood transfusions. Haematologist Dr. Rahul Bhargava highlights the significance of this drug, as it directly targets the metabolic pathway of red blood cells, offering a potential life-changing impact for thalassemia patients worldwide.
India, known as the thalassemia capital, faces challenges with blood availability, transfusion-related issues, and iron overload. While bone marrow transplants are expanding, most patients rely on lifelong transfusions. The introduction of this oral therapy brings hope for both transfusion-dependent and non-transfusion-dependent thalassemia patients, potentially delaying or preventing the progression to transfusion dependence. Experts are optimistic about the drug’s availability in India, foreseeing positive outcomes for patients and the healthcare system.
